Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Boo,
I agree 100%. On a different note, I hope they are able to get favorable new lease terms.
I guess it's a matter of trust or
Let's hope.
Was Dr. Kramer(Colorado resident) treated in Mongolia(where the phase 2 liver cancer trial occurred(and current phase 3 trial is taking place)? He claims to be patient #24 in the youtube presentation, as ph 2 trial patient # 24.
Just curious. Left a message with him, no response as of now.
My nomination for ipix theme song:
I think I disagree with your intereptation. Are you saying all patients are followed for 16 weeks after their last visit? If so, that is not my understanding.
The way I interpret the collection and assessment of endpoints is that documentation of conditions start at baseline(first review of patient prior to treatment) with most endpoints final measurements taken at end of treatment(12 weeks) or at final visit((16 weeks, which is 4 weeks from end of treatment)).
Secondary endpoints #s 8&9, plasma concentrations of prurisol and abacavir respectively, have a time frame of 4 weeks and were to be measured in a subset(not defined) of patient.
They announced the final patient visit(no more follow up) 107 days ago on 12/21/17(15.28 weeks ago).
ps- what do mean by data treatment?
One way or another, Sullivan shall be our savior.
I know the price of peanuts in banana growing country and have those markets cornered.
MackG,
¨Purisol is a winner, and it will be the Big Pharms who are desperate to get a piece of the awesome IPIX drug pipeline.¨
How do you know this?
Edward,
Please don´t shake up the offense.
Excellent observations. That post is disturbing, on a few levels.
https://www.ftc.gov/news-events/media-resources/truth-advertising
99 days since the 12/21/17 announcement that the last patient follow-up was completed(the visit likely occurred prior to 12/21/17). Anyhow, 14.5 weeks since the announcement, so your 16 weeks is probably close.
Sox,
True. What also adds time is the difference in outcome measures between the two trials.
P2a, 115 patients, 1 primary outcome measure(OM), 5 secondary OM.
P2b, 199 patients, 2 primary OMs, 9 secondary OM´s
199/115= 1.73, or 73% more patients
11/6= 1.8333, or 83% more outcome measures.
If they use the same staff as the P2a trial, we´re looking at ¨theoretically¨ ~30 weeks((1.78*17 weeks) I realize the comparison is not linear)).
Hopefully, the cro´s, or whoever is charged with the analysis, have more hands involved with P2b than the P2a trial, the wind picks up, and we sail out of these doldrums soon.
Did you mean to say ¨not all¨, or ¨none¨, instead of ¨All¨?
TB12NH,
I´m beginning to believe DaubersUP is part and parcel of this show. Appears ipix is now focusing on eye disease, based on his/her sentence(¨All drugs do what they have said they will do, but a couple do need reformulation for optical dosing.¨;)
Sullivans reputation is on the line.
Its appearing to look as though its tough to get things done from Boca.
I don´t think well see LE in Hopkinton on the 16th. He´ll need a nap after the plane flight.
https://en.wikipedia.org/wiki/Johnny_Kelley
Humorous response. But, I will declare, that we who have hung on, have had our buns burned.
Some good points. There are many dynamics in most decisions. Could be they....
AB from 11/30/17 p:“With all patients having received treatment, we look forward to wrapping up the Phase 2b Prurisol trial,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “Only a handful of patient follow-up visits remain to be completed. A novel psoriasis drug, particularly one that is oral, safe and effective, would be well-received by clinical practitioners and patients alike, both looking for newer treatment options to help manage this debilitating skin disease.”
As you note, the final visit was noted by the companys 12/21/17 pr.
The assessments(PSSTS) were done, once every two weeks as noted in the study design.
¨During treatment, subjects will return to the study center every 2 weeks. Efficacy assessments, including physician and patient rated endpoints, will be measured throughout the study. Safety and tolerability will be assessed by ascertainment of AEs and results of clinical laboratory testing, vital signs assessments, and need for concomitant medications.¨
¨I think we’ll all be waiting a long while for those articles.¨
I doubt it, but, we shall see.
¨I’ve read some articles in the past that companies like Novartis have hired off shore hedge funds to spread libel and cause pressure on the biotech it was attempting to buy.¨
Thx DaubersUP,
I don´t doubt it. Please share when you find those articles.
Betwixt and between.
Jhawker,
I hear you loud and clear, and experienced ¨ The insurance companies will only pay for certain things...¨ you noted.
This fall my endocrinologist suggested I switch basal insulin(from Lantus to a newer one called Tresiba). Checked with my insurance company and confirmed it was covered. Blood sugars had never been better with the new insulin(a1cs in the high 5s). Went to reorder another 90 day supply last month and was told by the pharmacy that insurance no longer covered it.
A patient will take whichever works best. If its determined that P works, then I´? sure some will use it.
Injections are not that complicated. As a type 1 diabetic, I can assure you of that(39 years now, got it as a kid). 5 to 6 times a day(one fast acting insulin for each meal, a basal(slow acting) insulin in the morning, and adjustment injections of the fast acting to prevent hyperglycemia as need be. Keep skittles within reach at all times for hypoglycemic episodes.
My first insulin was under an ongoing clinical trial(no longer manufactured), and nearly killed me(too many hypos).
Based on the company's pr´s, with quotes from patients and doctors, CDAs and BP interest, one would think B and P are a lock and the sp would rock.
We shall see.
sox040713,
Thanks for the otc.com link, I was not aware of it.
I trust the person you responded to was not aware of it either and was basing the 900,000 share figure(for which ipix received ~$600,000 between 1/1/18-2/7/18) as noted in the most recent 10q.
I have not checked out otc.com, and will assume the 1,500,000 shares you noted were sold by ipix to Aspire between today and 2/8/17, ~31 trading days. 1,500,000/31 trading days= 48387 share transaction between ipix and Aspire/day. So, I agree with your assessment.
I would have hoped it would have been less shares, bjt as the sp declines they need to sell more.
May good news hit us hard.
ps- opening season one week out-GO SOX
LR,
What are you implying?
Thx
LR,
¨Don't believe everything you read.¨
Reminds me of the saying, ¨the hand is quicker than the eye¨.
Justification, regardless of how the message is received, is key.
Appreciate your level-headed posts, ty.
123tom,
You state:
¨who would dump shares at the 50 cent open? not investors.
If an investor decided to bail out and give up on IPIX, they would wait for the next good bounce back to the resistance wall at 70 cents,recover many thousands of invested dollars, maybe break even, and get out.¨
I respectfully disagree. Everyone(investors included) is different and have different tolerance levels, and means of operation.
Farrell90,
You state¨I hope he has a no cut contract. This gig may be up soon.¨
1. What do you mean by no cut contract(ican infer, but would like to hear your definition?).
2. ¨This gig may be up soon.¨ What gig are you up to?
Excellent post. Reminds of something I recently read.
“To further these efforts, the Company is in negotiations with a leading drug formulator to develop topical formulation(s) of Brilacidin for these three dermatology indications, starting in 1H2018. The goal of the negotiations is to reach terms on a strategic partnership for addressing these markets. The formulator brings an impressive track record of developing products that have earned billions of dollars for global pharmaceutical companies.”
Excellent post. Reminds of something I recently read, last word modified.
¨.....you have posted this same crap at least 6 to 10 times. I guess you prescribe to the theory that no matter how untrue a statement is....the more times you say it will make people believe it to be true. This isn't politics...pumpster!!¨
The question is, whos you in the above quote?
So back to you DaubersUP, when do you want to meet with Sullivan et.al?
Big boy.
sox040713,
I agree with your thinking, hard to believe anyone could survive on a $232,925/yr (excluding stock options/ other perks).
May Daubers, or yourself, set the course straight shortly!
DaubersUP,
Impressed with your worldly experiences and your willingness to seek the truth. I'm with you. Lets arrange to have all of us who are concerned with the manipulators´ and are in New England(myself, TIAB(i think), you?(DaubersUP),(if not, you clearly can afford the cost to get here)) and anyone else, arrange a meeting with LE, Michael Sullivan(LE and he clearly know each other), Maura Healey, and perhaps a reputable news outlet(Hank Philipe Ryanhttps://en.wikipedia.org/wiki/Hank_Phillippi_Ryan).
I will arrange the meeting date and time, and make it happen. You tell me your availability. Clearly, LE is concerned about sp, as noted in the MAKO lawsuit. Clearly, TIAB is concerned about sp, as noted in his/her posts. Clearly, Maxamdud(sp??), as well as few others, are concerned based on past posts. Lets clear the air.
I´ve received some PMs(private messages) from some, of whom I consider the most respected and informative posters on this board, that are also not content. I, unfortunately, do not have PM, so to those that have responded privately(particularly one classy dame(who I shall not name), I am not ignoring you, and appreciate your responses. I will end this post by stating, that although all the investments I go into I expect a return, I believe we all have experienced some losses(nothing is a guarantee).
So back to you DaubersUP, when do you want to meet with Sullivan et.al?
kfc
¨What is there to be concerned about? Screw the stock share price performance. I’d like to know what I should be concerned about with IPIX?¨
The last time the sp closed above 0.75 was 1/30/18 when it closed at 0.76. That was 33 trading days ago(48 calendar days ago). As you know, Aspire loses the desire(not allowed) if/when sp hits 0.25. Thank God we have the shelf, so I´m not concerned. It's just we loyal shareholders who lose(¨önly if one sells¨).
Interesting that you´ve been around the world. Trust the trip was by design and that it was not the result of a wrong turn.
C?on DaubersUP,
Who can be satisfied with the performance of this investment whether it be in the past few days, weeks, months, or past few years?
Hopefully that all changes ¨in ?he coming weeks¨.
frrol,
Very good response. Does k modulate a better response or, worse? That is the next stone to unturn.
Thx for your clear, concise response.
kfc
Next week could(should, theyre dragging) be a good time to be unblinded, WILL II BE? If NOT, what are your expectations?
¨Only buy what you can lose of course. ¨
Nice response. Currently, ones´ loss pays the company´s salaries and bills.
That hopefully changes, and changes soon.
PP,
You will have to ask LE. Those words you are wondering about are in LEs quote that I referenced.
¨Time for this thing to move in the other direction.¨
Long past. They clearly need a deal. The four company officers(LE, KM, AB, and JH) require outlays of $3750/calander day(not a business day) or $26,250/week. Never mind all other expenses such as the rest of the staff, rent, utilities, vehicles, consultants, flights, hotels, insurance, etc,etc.
LE makes $1,276/cal day while AB makes $1,230/cal day. It adds up fast.